Emergen Research latest document, titled ‘Global Tumor Genomics Market - Forecast to 2027,’ is one of the most sought-after market reports involving an in-depth analysis of the global Tumor Genomics market. The report’s authors have offered necessary details on the latest Tumor Genomics market trends and the crucial parameters impacting both short-term and long-term market growth. Its panoramic view of the Tumor Genomics industry entails useful insights into the estimated Tumor Genomics market size, revenue share, and sales distribution network such helpful market insights are bound to help readers outline this industry’s key outcomes in the near future.

Increasing number of cancer cases, rising government initiatives and projects, new drug developments, and increasing demand for cancer-specific diagnostics are factors driving global tumor genomic market growth.Tumor Genomics  Market Size – USD 21.42 Billion in 2020, Market Growth – at a CAGR of 12.8%, Market Trends – Next generation sequencing techniques and new drug discoveries.

Get a Free sample of the report : https://www.emergenresearch.com/request-sample/531

Mergers and acquisitions between key players in the field is another key factor driving market growth. Increasing research on cancer, usage of genomic systems among academics and government institutions, and decreasing cost of sequencing is contributing significantly to growth in cancer diagnostics. Moreover, advances in computational approaches in tumor genomics has resulted in shorter result time, which is a key factor driving adoption, and thus driving growth of the market. Tumor is often caused by genetic alterations, including gene fusions, large chromosomal rearrangements; however, next generation sequencing techniques have helped researchers gather vast amounts of tumor genomic data and record genetic mutations in various cancer types.

Key Highlights of Report

In September 2018, Cancer Genetics Inc. and NovellusDx Ltd. signed a merger agreement in order to combine their data associated to tumor anatomy. The aim behind the merger is to enhance and accelerate the therapeutic development to improve treatment success rates for companies. With the proprietary technology and machine learning technology of NovellusDX Ltd., Cancer Genetics aims to form a leading oncology-focused precision medicine company.

Biomarkers play an important role in the detection of cancer and it may be used to detect early cancer symptoms or to perform differential diagnosis of cancerous tumors.

Revenue from the tumor genomic market in Asia Pacific is expected to expand at a rapid CAGR during the forecast period. This can be attributed to rising government funding for cancer detection and awareness, and introduction of state-of-the-art research institutions.

Key players in genomic biomarkers are Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Pacific Biosciences of California, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., and PerkinElmer.

Competitive Terrain:

 The Global Tumor Genomics Market is highly consolidated due to the presence of a large number of companies across this industry. The report discusses the current market standing of these companies, their past performances, demand and supply graph, production and consumption patterns, sales network, distribution channels, and growth opportunities in the market at length

Request customization of the report: https://www.emergenresearch.com/request-for-customization/531

Emergen Research has segmented the global tumor genomic market on the basis of technique, application, end-use, and region:

Technique Outlook (Revenue, USD Billion; 2021–2028)

• Next Generation Sequencing Technique (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray
• In-Situ Hybridization (ISH)
• Immunohistochemistry (ICH)
• Others (Mass Spectrometry and Flow Cytometry)

Application Outlook (Revenue, USD Billion; 2021–2028)

• Diagnostics and Monitoring
• Drug Discovery and Development
• Biomarker Discovery

End-use Outlook (Revenue, USD Billion; 2021–2028)

• Academics and Research Organizations
• Hospitals and Ambulatory Clinics
• Clinical and Diagnostic Laboratories
• Biotechnology and Pharmaceutical Company

Overview of the Tumor Genomics Market Report:

Introduction, Product Scope, Market Overview, and Opportunities

Analysis of the Manufacturers with sales, revenue, and price analysis

Comprehensive analysis of the competitive landscape

Extensive profiling of the key competitors along with their business strategies and market size

Regional analysis of the market along with sales, revenue, market share, and global position

Country-wise analysis of the market along with types, applications, and manufacturing

Strategic recommendations to established players as well as new entrants

In-depth analysis of the risks, restraints, and limitations in the Tumor Genomics industry

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East Africa.

Read More: https://www.emergenresearch.com/industry-report/tumor-genomics-market

Related Reports:

About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research         and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkdIn | Twitter | Blogs